Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) Director Sells $1,624,000.00 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Director Jennifer Mckie Adams sold 50,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Eton Pharmaceuticals Price Performance

ETON opened at $32.48 on Friday. The stock’s 50 day simple moving average is $29.07 and its 200 day simple moving average is $21.67. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. Eton Pharmaceuticals, Inc. has a 1 year low of $13.09 and a 1 year high of $35.66. The firm has a market cap of $889.63 million, a price-to-earnings ratio of -463.93 and a beta of 0.87.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.05). The company had revenue of $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. As a group, analysts predict that Eton Pharmaceuticals, Inc. will post 0.75 earnings per share for the current year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently modified their holdings of the stock. Quarry LP bought a new position in Eton Pharmaceuticals in the third quarter worth about $37,000. Legal & General Group Plc bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd bought a new stake in Eton Pharmaceuticals during the 4th quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Eton Pharmaceuticals during the 4th quarter worth approximately $74,000. Finally, SG Americas Securities LLC purchased a new position in shares of Eton Pharmaceuticals during the 4th quarter worth approximately $109,000. Institutional investors own 27.86% of the company’s stock.

Analyst Ratings Changes

ETON has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. HC Wainwright raised their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. B. Riley Financial upped their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Finally, Craig Hallum increased their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $41.00.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.